Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ketorolac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 0.92 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.92 |
| ▸ | CDC42 | P60953 | 3/20 | 0.92 |
| ▸ | RAC1 | P63000 | 3/20 | 0.92 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.92 |
| ▸ | NPC1 | O15118 | 2/20 | 0.92 |
| ▸ | RAB9A | P51151 | 2/20 | 0.92 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.92 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.92 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | CA4 | P22748 | 5/20 | 0.56 |
| ▸ | CA9 | Q16790 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketorolac SCHEMBL14892 | 0.96 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL23466702 | 0.96 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL14891 | 0.96 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL4103 | 0.96 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL5301763 | 0.94 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL28826490 | 0.94 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL28470790 | 0.94 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL15661224 | 0.94 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL20553125 | 0.94 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL18797655 | 0.94 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156738-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-05-16 | — | — | US | disclosed |
| US-11939333-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | INFINITY PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240050437-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2024-02-15 | — | — | US | disclosed |
| US-11752106-B2 | Pharmaceutical composition and administrations thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-12 | — | — | US | disclosed |
| CN-113616656-B | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders | 无限药品股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-4066834-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20220135576-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| CN-114230571-A | Solid forms of isoquinolinones, methods of making, compositions containing, and methods of use thereof | 无限药品股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-11247995-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | INFINITY PHARMACEUTICALS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2013130669-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATION THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130224293-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013032591-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2013012915-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012918-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20110183948-A1 | TREATMENT OF FIBROTIC CONDITIONS USING HEDGEHOG INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2011088404-A1 | TREATMENT OF FIBROTIC CONDITIONS USING HEDGEHOG INHIBITORS | INFINITY PHARMACEUTICALS , INC (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050437-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PTGS2 1742/4885PTGS1 1405/4885CDC42 536/4885 |
| US-20130224293-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KCNQ5 | PTGS2 777/4885PTGS1 814/4885CDC42 3682/4885 |
| US-20110183948-A1 | TREATMENT OF FIBROTIC CONDITIONS USING HEDGEHOG INHIBITORS | SHH, GLI1, SMO | PTGS2 621/4885PTGS1 416/4885CDC42 1547/4885 |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | PTGS2 3117/4885PTGS1 2224/4885CDC42 429/4885 |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PTGS2 1742/4885PTGS1 1405/4885CDC42 536/4885 |
| US-20240156738-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KCNQ5 | PTGS2 813/4885PTGS1 841/4885CDC42 3646/4885 |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | PTGS2 1742/4885PTGS1 1405/4885CDC42 536/4885 |
| US-11752106-B2 | Pharmaceutical composition and administrations thereof | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KCNQ5 | PTGS2 813/4885PTGS1 841/4885CDC42 3646/4885 |
| US-11247995-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | PIK3CA, PIK3C2A, PIK3CD | PTGS2 1939/4885PTGS1 1533/4885CDC42 1024/4885 |
| US-20220135576-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PIK3CA, PIK3C2A, PIK3CD | PTGS2 1939/4885PTGS1 1533/4885CDC42 1024/4885 |
| US-11939333-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | PIK3CA, PIK3C2A, PIK3CD | PTGS2 1939/4885PTGS1 1533/4885CDC42 1024/4885 |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PTGS2 1742/4885PTGS1 1405/4885CDC42 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.